Nuremberg researchers develop world’s first monoclonal antibody against vasoinhibin

Nuremberg — Scientists at Nuremberg Hospital and Paracelsus Medical University have succeeded in developing the world’s first monoclonal antibody that specifically and sensitively detects vasoinhibin — also known as 16-kDa prolactin (16K PRL). The international patent application PCT/EP2024/073698, published under the number WO2025098661A1, protects the antibody itself as well as its specific use in standardized diagnostic test systems, including a novel ELISA kit. The patent application also paves the way for the establishment of an international reference laboratory for vasoinhibin measurement.

Full press release: http://idwf.de/-DUN0AA